HOLISTIC Trial: Using Embedded Pharmacists to Improve CKM Syndrome Care
Six health systems are launching the HOLISTIC trial in early 2027 to embed pharmacists in primary care clinics, aiming to test whether team-based medication management can improve outcomes for patients with cardiovascular-kidney-metabolic syndrome. Healthcare Innovation reported that the implementation study runs through 2030.
Cardiovascular-Kidney-Metabolic Syndrome Meets Primary Care Integration
The trial addresses a persistent care-delivery gap by placing clinical pharmacists directly inside primary care settings. These pharmacists manage medications and lift the daily workload from primary care physicians.
Nephrology and cardiology specialists support the embedded pharmacists through weekly case conferences modeled after tumor boards. Specialists review every high-risk case involving diabetes and chronic kidney disease to guide rapid drug implementation.
Six health systems participate in the initiative: Providence, UCLA Health, UT Southwestern, University of North Carolina, Brigham and Women’s Hospital, and the University of Minnesota. The Baim Institute for Clinical Research in Boston coordinates the multi-site study.
Providence deploys the model across six primary care clinics in the Spokane, Washington region and Colville. Three clinics continue with usual care, while the other three receive an embedded pharmacist working weekly with specialists.
Researchers measure how quickly and effectively guideline-directed medical therapy gets implemented. The study also tracks hard clinical endpoints including mortality, hospitalizations, dialysis, and heart disease events.
Evaluating Past Failures Against Upstream Breakthrough Therapies
The Center for Medicare & Medicaid Innovation watches the trial closely following the modest performance of previous value-based frameworks. Katherine Tuttle, executive director for research at Providence Inland Northwest Health, noted that CMMI’s Kidney Care Choices Model focused primarily on advanced stages four and five.
That earlier model relied on older medications like ACE inhibitors and ARBs while prioritizing optimal dialysis starts and transplants rather than early kidney health preservation. Those previous models yielded less than a 10 percent improvement across target metrics.
In the reporting year of 2023, those programs cost $300 million more. Tuttle received both the 2026 Clinical Research Prize and the 2026 Distinguished Service Award from the American Heart Association for her scientific work.
Therapeutic options have expanded dramatically over the past five years. Clinicians now utilize SGLT2 inhibitors, nonsteroidal mineralocorticoid receptor antagonists like finerenone, and GLP-1 receptor agonists.
Independent of blood glucose reduction or weight loss, GLP-1 medications provide notable kidney-protective benefits. Combining these newer classes creates additive physiological advantages for patients.
Early Detection Could Decrease Kidney Failure by 55 Percent
Mathematical modeling indicates that early detection and treatment among patients in chronic kidney disease stage 3—defined as a glomerular filtration rate below 60—could decrease the frequency of kidney failure by 55 percent. Achieving this requires prompt identification before vital organ damage becomes irreversible.
Translating clinical evidence into routine practice historically requires an average duration of 17 years. The HOLISTIC trial attempts to compress that timeline through pragmatic implementation.
Baim Institute’s economic research group conducts a health economic study alongside clinical evaluations. CMMI officials engaged with study leaders to explore potential scaling, including integration within rural settings and federally qualified health centers.
Policy changes must follow positive trial results to alter payment structures permanently. Tuttle emphasized that proving the intervention works in primary care is the vital final step in closing the execution gap.
“The outcome will be whether or not people get guideline-directed medical therapy, how quickly it’s implemented, and then importantly for the health system, we’ll be looking at the major outcomes: mortality, hospitalizations, dialysis, heart disease events,” Tuttle told Healthcare Innovation.